A transformative wound management approach with BMG™ technology – final report of a national 80 patient case study series.  

– Joy Tickle,  Tissue Viability Nurse Consultant

Abstract

Introduction

Affecting approximately 3.8 million people in the UK, chronic wounds can heavily impact a person’s life. Patients with a wound experience pain, discomfort and loss of mobility which can affect their quality of life and, in severe cases, be debilitating. Unhealed wounds can also have a notable effect on a person’s mental health, with patients experiencing issues such as depression and anxiety (Fearns, N et al 2017).

A chronic wound should prompt the healthcare professional to begin a search for unresolved underlying causes. Healing requires care that is patient centred, holistic, interdisciplinary, cost effective and evidence based. Underlying causes and factors interfering with wound healing may be multifactorial. It is well accepted that wounds heal in four phases: Haemostasis, Inflammation, Proliferation and Maturation, chronic wounds being no exception.

Advancing technologies can facilitate healing by providing solutions against barriers to healing, augmentation of wound healing factors, and optimization of the ultimate results of wound reconstruction.

Wound healing is not linear and often wounds can progress both forwards and back through the phases depending upon intrinsic and extrinsic forces. (Shanker, M 2014) Bioactive Microfibre Gelling (BMG™) technology in the evaluated advanced woundcare dressing utilizes chitosan to maintain a cohesive structure increasing fluid handling, antimicrobial and wound healing properties.

Chitin and chitin derivatives havebeen reported to promote rapid dermal regeneration and accelerate wound healing. (Dai, T et al 2011)

Method

Following local guidelines and obtaining Trust and patient consent, the aim was to assess the performance of a BMG technology dressing across various wound types in a variety of clinical settings.

Primary objective – to assess overall clinical acceptability for indications treated.

Secondary objectives – assessing dressing performance characteristics, determining changes in wound outcomes over the course of treatment, and clinicians’ level of satisfaction with product characteristics.

Eighty-two adult patients, with a total of eighty-nine wounds, were recruited from twelve clinical settings. Patients were reviewed weekly for a period of 4 weeks which was sufficient to provide information on product and clinical performance.

Of the patients recruited, wound types included;

  • diabetic foot ulcers (8%)
  • venous leg ulcers (20%)
  • oncology wounds (17%)
  • trauma wounds (5%)
  • pressure ulcers (25%)
  • others (25%)

Wounds categorised as ‘Others’ include, but are not limited to; surgical wounds, pyoderma gangrenosum, mixed aetiology leg ulcers.

Wound duration at initial assessment ranged from 0.5 months (3%) to over 12 months (27%)

 

To read the full poster, and see the results of this multi centre evaluation click here.

Unhealed wounds can also have a notable effect on a person’s mental health, with patients experiencing issues such as depression and anxiety.

Fearns, N., Heller-Murphy, S., Kelly, J., Harbour, J. Placing the patient at the centre of chronic wound care: A qualitative evidence synthesis. Journal of Tissue Viability, Vol 26, Issue 4, Nov 2017 pp 254-259.

Wound duration at initial assessment ranged from 0.5 months (3%) to over 12 months (27%)

References

(1) Fearns, N., Heller-Murphy, S., Kelly, J., Harbour, J. Placing the patient at the centre of chronic wound care: A qualitative evidence synthesis. Journal of Tissue Viability, Vol 26, Issue 4, Nov 2017 pp 254-259.

(2) Wound Healing and its importance – Areview, Shankar M. et al. / Der Pharmacologia Sinica. 2014;1(1):24-30.0

(3) Dai T, Tanaka M, Huang VY, Hamblin MR. Chitosan preparations for wounds and burns: antimicrobial and wound-healing effects. Expert review of anti-infective therapy. 2011 Jul1;9(7):857-79.

(4) CD Medical, Data on file.

 

 

Request a Sample of MaxioCel

Contact us to arrange a demonstration and sample of MaxioCel, and find out more about the benefits for your patients.